Additionally, 17 potential therapeutic targets (AKT1, CCND1, CASP3, CTNNB1, EGF, EGFR, ESR1, HIF1A, HSP90AA1, IL6, JUN, MYC, MAPK3, PTEN, STAT3, TP53, VEGFA) were directly related to the KEGG pathway “cancer” and linked to 30 compounds (SQ7, ZJ11, ZJ3, ZJ4, CBM9, CF2, CF3, QYS8, QYS9, ZJ8, CL3, CL5, ZJ6, CL2, ZJ10, ZJ12, ZJ2, DSL4, DSL5, DSL6, ZZS1, CF1, CF10, GC12, GC16, GC37, QYS3, SQ13, XYS24, CBM16; Table S2). Here, ESR1 is linked to cancer.